Canada Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Canada Breast Cancer Therapeutics Market Analysis

$ 3999

The Canada breast cancer therapeutics market size is valued at $1.45 Bn in 2022 and is estimated to expand at a compound annual growth rate of 12.9% from 2022 to 2030 and will reach $3.84 Bn in 2030 and this rise is attributed to the novel therapies for curing breast cancer and increasing research and development activities in Canada. The market is segmented by therapy, by cancer type and by distribution channel. Some of the leading companies in the market are Johnson & Johnson Services Inc., Pfizer Inc., AbbVie Inc., etc.

ID: IN10CAPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Canada

Buy Now

Canada Breast Cancer Therapeutics Market Executive Analysis

The Canada breast cancer therapeutics market size is at around $1.45 Bn in 2022 and is projected to reach $3.84 Bn in 2030, exhibiting a CAGR of 12.9% during the forecast period. According to the Canadian Institute for Health Information (CIHI), Canada's total healthcare expenditures will amount to $242.6 Bn in 2020, or 11.6% of the GDP of the nation. This amount is expected to increase over the next few years as a result of factors including an aging population and growing healthcare costs. The majority of healthcare costs are covered by the government in Canada through public insurance programs like Medicare. Out-of-pocket expenses and private insurance also have an impact on healthcare spending.

According to the Canadian Cancer Society, breast cancer is the most commonly diagnosed cancer among Canadian women. In Canada, 1 in 9 women is expected to develop breast cancer in their lifetime. However, the death rate from breast cancer has been declining over the last few decades due to advances in treatment and early detection through screening programs. In Canada, breast cancer is treated with a combination of surgery, radiation therapy, chemotherapy, and hormone therapy. The specific treatment plan will depend on the stage and type of breast cancer and the patient's overall health.

Canada Breast Cancer Therapeutics Market Size

Market Dynamics

Market Growth Drivers

The development of new and innovative therapeutics, such as immunotherapy, CAR-T therapy, and targeted therapies is expected to drive market growth in Canada. Pharmaceutical companies in Canada are investing in research and development activities to develop new breast cancer therapeutics. Increasing awareness and screening programs for breast cancer in Canada will eventually lead to growth in the market.

Market Restraints

Certain targeted therapies resulting in side effects like skin problems, diarrhoea, and fatigue are potential restraints to the market growth of breast cancer therapeutics in Canada. Also, the rising costs of treatment of breast cancer may limit the market growth in Canada.

Competitive Landscape

Key Players

Johnson & Johnson Services Inc. (CAN)
Pfizer Inc. (CAN)
AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
Bristol-Myers Squibb Co.
Eli Lilly and Co.
Halozyme, Inc.
Merck & Co., Inc.

Healthcare Policies and Regulatory Landscape.

In Canada, breast cancer therapeutics are covered under the national public healthcare system, which is called Medicare. Canadian citizens and permanent residents have access to breast cancer therapeutics without having to pay out-of-pocket costs, and the coverage is provided through hospitals and clinics, cancer care centers, and oncologists' offices. The coverage for breast cancer therapeutics includes surgery, radiation therapy, chemotherapy, hormone therapy, and targeted therapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.